NCT01303094 2026-03-16
T-DIS
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
18 trialsNCT04008238 2026-03-06
PIPER
Institut Bergonié
Phase NA Completed
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02367924 2023-06-22
YonSar
PharmaMar, Spain
Completed
NCT03590210 2022-11-08
NiTraSarc
University Medicine Greifswald
Phase 2 Completed
NCT02398058 2021-04-14
TOMAS
Italian Sarcoma Group
Phase 1 Completed
NCT04394728 2020-05-19
Metabol-STS
Centro di Riferimento Oncologico - Aviano
Completed
NCT02793050 2019-05-10
TrObs
Italian Sarcoma Group
Completed
NCT02672527 2018-08-16
TSAR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT01692678 2018-07-11
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Completed
NCT00379145 2017-12-12
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
GOG Foundation
Phase 2 Completed
NCT01453283 2017-07-02
Tabectedin to Treat Children and Adolescents With Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00796120 2015-12-10
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00786838 2014-04-11
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00017030 2013-06-26
Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005625 2013-06-19
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00102609 2013-01-10
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 1 Completed
NCT00003939 2012-09-24
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed